Locally Advanced NSCLC
126TiP SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC): A multicenter single-arm phase II trial

https://doi.org/10.1016/S1556-0864(18)30399-XGet rights and content
Under an Elsevier user license
open archive

Cited by (0)